Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

20253 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov, NCT04392154.

Published in: Dermatology and Therapy

Volume 15, Issue 8, pp. 2217-2232

Field-Weighted Citation Impact: 6.32